Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
116.89(c) 115.28(c) 115.91(c) 116.87(c) 118.85(c) Last
4 372 526 8 172 099 6 293 338 4 919 820 6 415 009 Volume
+0.33% -1.38% +0.55% +0.83% +1.69% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 56 248 M - -
Net income 2021 11 044 M - -
Net Debt 2021 63 490 M - -
P/E ratio 2021 19,1x
Yield 2021 4,38%
Sales 2022 59 786 M - -
Net income 2022 14 980 M - -
Net Debt 2022 50 649 M - -
P/E ratio 2022 13,3x
Yield 2022 4,71%
Capitalization 210 B 210 B -
EV / Sales 2021 4,86x
EV / Sales 2022 4,36x
Nbr of Employees 50 000
Free-Float 98,0%
More Financials
Company
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human... 
Sector
Pharmaceuticals
Calendar
12/11Presentation
More about the company
Ratings of AbbVie Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ABBVIE INC.
12/03FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
RE
12/03AbbVie Labeling for Rheumatoid Arthritis Drug Rinvoq Updated to Include Cancer, Cardiov..
MT
12/03AbbVie Provides Update on RINVOQ« (upadacitinib) for the Treatment of Rheumatoid Arthri..
PR
11/30AbbVie Seeks European Approval for Risankizumab in Moderate to Severe Crohn's Disease
MT
11/30ABBVIE : The Alliance for Endometriosis Survey Reveals Actions Needed to Improve the Endom..
PU
11/30AbbVie Submits Europe Application for Risankizumab for Crohn's Disease
DJ
11/30AbbVie Submits Application for Risankizumab (SKYRIZI«) in Moderate to Severe Crohn's Di..
PR
11/30AbbVie Submits Application for Risankizumab (SKYRIZI?) in Moderate to Severe Crohn's Di..
CI
11/24Truist Adjusts Price Target on AbbVie to $135 From $118, Maintains Buy Rating
MT
11/24NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/23AbbVie Shares Rise After Societe Generale's Upgrade, Price Target Hike
MT
11/23Societe Generale Upgrades AbbVie to Buy from Hold, Raises Price Target to $172 From $11..
MT
11/23WALL STREET STOCK EXCHANGE : The Fed cannot stop Covid
11/23AbbVie to Present at the Evercore ISI Conference
PR
11/23AbbVie to Present at the Piper Sandler Healthcare Conference
PR
More news
News in other languages on ABBVIE INC.
12/03Mise à jour de l'étiquetage de Rinvoq, le médicament d'AbbVie contre la polyarthrite rh..
11/23Les actions d'AbbVie augmentent après la mise à jour de la Société Générale et la hauss..
11/17Skyrizi d'AbbVie obtient l'autorisation de l'Union européenne pour le rhumatisme psoria..
11/11INVENTIVA : hausse de la trésorerie au 30 septembre malgré des coûts de R&D plus élevés
11/10AbbVie et l'Université de Chicago prolongent leur partenariat de recherche en oncologie..
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 118,85 $
Average target price 130,14 $
Spread / Average Target 9,50%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.8.18%210 113
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641